Glycolyl-sialyated mucin antigen 3EG5-serum marker of activity and severity of interstitial lung diseases
Abstract
We have constructed a sandwich immunoassay for detection of glycolyl-sialylated glycoprotein (mucin) antigen 3EG5 using a monoclonal antibody 3E 1.2 and affinity-purified polyclonal antibody G5 reactive against total mucin antigen family. Increased levels of mucin antigens may reflect the proliferation of Type 2 pneumocytes in chronic pneumonitis.
Using this assay, we have quantified a serum mucin in patients with interstitial lung diseases (ILD): idiopathic pulmonary fibro sis (IPF) and hypersensitivity pneumonitis (HP); bronchial asthma (BA); chronic obstructive pulmonary disease (COPD); other pulmonary diseases and healthy control subjects (hospital personnel). An arbitrary cut-off 75 U nits/m l (U /m l) was set as m ean+2SD (n=52) of healthy subjects. The serum level o f 3EG5 in patients with ILD was prominently greater (225,9 ± 112,1 U /m l, range: 108 — 595 U /m l; n=28) than in patients with BA (68 ,9 ±3 ,3 U /m l; л=40), COPD (59,5±30,8U /m l; л = 1 8), pneumonia (4 8 ,9 ± 3 1 ,1 U /m l; /7=20). The elevated serum mucin 3EG5 was detected in all studied forms of ILD. The degree of serum mucin elevation correlated with severity of clinical symptoms: dispnea score (r=0,73; p< 0,001), radiographic profusion score (r=0,43; p-0,020), degree of restrictive changes in pulmonary function tests (TLC: r= -0,46; p= 0,015; FVC: r= -0,46; p < 0,05; DLCO: r= -0,64 ; p < 0,001) and neutrophyle count in bronchoalveolar lavage fluid (/=0,87; p< 0 ,0 0 1 ) (for IPF).
We conclude that determination of serum mucin 3EG5 may contribute to diagnosing of ILD and m ay reflect activity and severity of these diseases.
About the Authors
O. Avdeeva
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
Y. Lebedin
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
S. Avdeev
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
S. Chukanov
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
A. Cherniack
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
M. Samsonova
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
A. Chuchalin
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
References
1. Соrrun В. Pathology of interstitial lung disease / / Semin. Respir. Crit. Care M ed.— 1994.— V ol.15, № 61.— P .76.
2. Cotes J.E., Chinn D.J., Quanjer Ph.H., Roca J., Yernault J.C. Standartization of the m easurem ent of transfer factor (diffusing capacity) / / Eur. Respir. J.— 1993.— Vol.6, Suppl. 16.— P.41—52.
3. Crystal R.G., Gadek J.E., Ferrans V.J., Fulmer J.D., Line B.R., Hunninghake G.W. Interstitial lung disease: current concepts of pathogenesis, staging and therapy / / Am. J. M ed.— 1981.— Vol.70.— P.542—567.
4. Ferris B.G. Epidemiology standartization project. Use of chest radiography in epidemiological studies of non-occupational lung disease / / Am. Rev. Respir. Dis.— 1978.— V ol.118, Suppl.6.— P.89—111.
5. Haslam P.L., Poulter L.W., Rossi G.A. et al. The clinical role of BAL in idiopathic pulmonary fibrosis / / Eur. Respir. J.— 1990.— Vol.3.— P.940—942.
6. Hilgers J., Von Mensdorff-Poully S., Verstraeten A.A., Kenemans P. Q uantitation of polymorphic epithelial mucin: a challenge for biochem ists and immunologist / / Scand. J. Clin. Lab. Invest.— 1995.— Vol.55, Suppl.221.— P.81—86.
7. Honda Y., Kuroki Y., Matsuura E. Pulm onary surfactant protein D in sera and bronchoalveolar lavage fluids / / Am. J. Respir. Crit. Care M ed.— 1995.— V ol.152.— P.1860—1866.
8. Honda Y., Kuroki Y., Shijubo N. et al. A berrant appearance of lung surfactant protein A in sera of patients with idiopathic pulmonary fibrosis and its clinical significance / / Respiration.— 1995.— Vol.62.— P.64—69.
9. Johnston I.D.A., Prescott R.J., Chalmers J.C. et al. British Thoracic Society study of cryptogenic fibrosing alveoltis: current presentation and initial m anagem ent / / Thorax.— 1997.— Vol.52.— P.38—44.
10. Kleich H., Hutter C. Clinical guidelines and indications for bronchoalveolar lavage (BAL): Report of the European Society of Pneumology Task Group on BAL / / Eur. Respir. J.— 1990.— Vol.3. P.937—969.
11. Kobayashi J., Kitamura S. KL-6: a serum marker for interstitial pneumonia / / C hest.— 1995.— V ol.108.— P.311—315.
12. Konho N., Kyoizumi S., Awaya Y., Fukuhara H., Yamakido М., Akiyama M. New serum indicator of interstitial pneumonitis activity: sialyated carbohydrate antigen KL-6 / / Ibid.— 1989.— Vol.96.— P.68—73.
13. Konho N., Awaya Y., Oyama Т., et al. KL-6, a mucin-like glycoprotein, in bronchalveolar lavage fluid from patients with interstitial lung disease / / Am. Rev. Respir. Dis.— 1993 - Vol. 148.— P.637—42.
14. Kohno N., Yokoyama A., Hirasawa Y., Kondo K., Fujino S., Abe М., Hiwada K. Comparative studies of circulating KL-6, type III procollagen N-terminal peptide and type IV collagen 7S in patients with interstitial pneumonitis and alveolar pneumonia / / Respir. Med.— 1997.— Vol.91.— P.558—561.
15. Kuroki Y., Tsutahara S., Shijubo N. et al. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis / / Am. Rev. Respir. Dis.— 1993.— Vol.147.— P.723—729.
16. McCormack F.X., King T.E., Voelker D.R., Robinson P.C., Mason R.J. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A / / Ibid.— 1991.— Vol.144.— P.160—166.
17. Milman N., Kristensen M.S., Bentsen K. Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid from patients with pulmonary fibrosis / / APM IS.— 1995.— Vol.103.— P.749—754
18. Quanjer Ph.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.C. Lung volumes and forced ventilatory flows / / Eur. Respir. J .— 1993.— Vol.6, Suppl. 16.— P.5—40.
19. Raghu G. Interstitial lung disease: a diagnostic approach / / Am. J. Respir. Crit. Care.— 1995.— Vol.151.— P .909—914.
20. Satoh H., Kamma H., Ogata Т., Yano H., Ohtsuka М., Hasegawa S . Clinical significance of serum levels of a carbohydrate antigen, syalyl antigen SSEA-1, in patients with fibrosing lung disease / / Am. Rev. Respir. Dis.— 1991.— Vol.144.— P.1177—1181.
21. UICC/Cincinnati classification of the radiographic appearences of pneumoconiosis / / C hest.— 1970.— Vol.58.— P.57—67.
22. Watters L.C., King T.E., Schwarz M.J., Waldron J.A. et al. A clinical, radiographic and physiologic scoring system for the longitudinal assessm ent of patients with idiopathic pulmonary fibrosis. / / Am. Rev. Respir. Dis.— 1986.— Vol. 133.— P.97—103.
23. Wells A.U., Hansell D.M., Harrison N.K., Lawrence R., Black C.M., du Bois R.M. Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis / / Eur. Respir. J .— 1993.— Vol.6.— P.797—802.
Review
For citations:
Avdeeva O., Lebedin Y., Avdeev S., Chukanov S., Cherniack A., Samsonova M., Chuchalin A. Glycolyl-sialyated mucin antigen 3EG5-serum marker of activity and severity of interstitial lung diseases. PULMONOLOGIYA. 1998;(2):22-27. (In Russ.)
Views:
176
Email this article 